Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Trial details
- Registry ID
- NCT05317819
- Drugs studied
- ADI-PEG20
TrialRedline tracks 5 clinical trials sponsored by Polaris Group: 2 Phase 3, 1 Phase 2 / 3, 2 Phase 2.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular CarcinomaNCT05317819 | ADI-PEG20 | Recruiting | 2028-09Estimated |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)NCT05712694 | ADI PEG20 | Terminated | 2026-05-25Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and CisplatinNCT02709512 | ADI-PEG 20 plus Pem Platinum | Completed | 2022-08-15Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Study of ADI-PEG 20 Versus Placebo in Subjects With NASHNCT05842512 | ADI-PEG20 | Recruiting | 2027-12-31Estimated |
| ADI-PEG 20 Plus Radiotherapy and Temozolomide in Subjects With Glioblastoma MultiformeNCT04587830 | ADI-PEG 20, Temozolomide | Active not recruiting | 2027-02-28Estimated |
Names as written in the registry records.
NCT05712694 · Polaris Group
Before: Estimated. After: Actual.
Before: 300 participants (planned). After: 218 participants (actual).
Before: Estimated. After: Actual.
Before: 30 Dec 2027. After: 25 May 2026.
Before: Recruiting. After: Terminated.
Before: Sep 2025. After: Sep 2028.